Citations

Showing 10 of 108083 citations.

The eye as a window to the brain
Pless, Misha L, Pless, Misha L

Mayo Clinic

Annals of the Academy of Medicine, Singapore | February 27, 2023 | Volume: 52 | Issue: 2 | Pages: 60-61

10.47102/annals-acadmedsg.202317 | PMID 36880816 Get It

Real‐world experience of tixagevimab‐cilgavimab pre‐exposure prophylaxis in orthotopic heart transplant recipients
Ordaya, Eloy E. , Higgins, Eibhlin , Vergidis, Paschalis , Razonable, Raymund R. , Beam, Elena , Higgins, Eibhlin M , Razonable, Raymund R , Vergidis, Paschalis , Beam, Elena

Mayo Clinic

Transplant Infectious Disease | February 27, 2023 | Volume: 25 | Issue: 3 | Pages: No page available

10.1111/tid.14040 | PMID 36847413 Get It

AbstractBackgroundPre‐exposure prophylaxis with tixagevimab‐cilgavimab (tix‐cil) may be associated with cardiovascular adverse events. Also, in vitro studies have reported a reduced activity of tix‐cil against emerging SARS‐CoV‐2 Omicron subvariants. Our study aimed to report the real‐world outcomes of tix‐cil prophylaxis in orthotopic heart transplant (OHT) recipientsMethodsWe retrospectively studied all OHT recipients who received one dose of tix‐cil (150–150 mg or 300–300 mg) at Mayo Clinic in Arizona, Florida, and Minnesota, between February 5, 2022 and September 8, 2022. We collected data on cardiovascular adverse events and breakthrough COVID‐19 following tix‐cil administration.ResultsOne hundred sixty‐three OHT recipients were included. The majority were male (65.6%), and the median age was 61 years (IQR 48, 69). During the median follow‐up of 164 days (IQR 123, 190), one patient presented an episode of asymptomatic hypertensive urgency that was managed with outpatient antihypertensive treatment optimization. Twenty‐four patients (14.7%) experienced breakthrough COVID‐19 at the median of 63.5 days (IQR 28.3, 101.3) after tix‐cil administration. The majority (70.8%) completed the primary vaccine series and received at least one booster dose (70.8%). Only one patient with breakthrough COVID‐19 required hospitalization. All patients survived.ConclusionsIn this cohort of OHT recipients, no patients developed severe cardiovascular events related to tix‐cil. The high incidence of breakthrough COVID‐19 could be due to the reduced activity of tix‐cil against current circulating SARS‐CoV‐2 Omicron variants. These results emphasize the need for a multimodal prevention strategy against SARS‐CoV‐2 in these high‐risk patients. image
State of the Art Medical Management of Nasal Polyps
Staricha, Kelly L., Ali, Hawa M. , Stokken, Janalee K. , Carlson, Matthew L

Mayo Clinic

American Journal of Rhinology & Allergy | February 27, 2023 | Volume: 37 | Issue: 2 | Pages: 153-161

10.1177/19458924221145256 | PMID 36848283 Get It

Background Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory disease with a treatment goal of controlling symptoms and limiting disease burden. While endoscopic sinus surgery is effective for removing polyps and aerating sinuses, proper medical management remains necessary for reducing inflammation and limiting polyp recurrence. Objective This article aims to summarize the literature regarding medical treatment of chronic rhinosinusitis with nasal polyposis, with a specific focus on developments in the past 5 years. Methodology We conducted a literature review using PubMed to identify studies assessing medical treatment strategies for patients with CRSwNP. Articles focusing on chronic rhinosinusitis without nasal polyposis were excluded unless specifically stated. Surgical treatment and biologic therapies for CRSwNP will be covered in subsequent chapters and are therefore not included. Results Intranasal saline irrigations and topical steroids are mainstays of CRSwNP treatment in the pre-surgical, post-surgical, and maintenance phases of the disease. Alternative steroid delivery methods and adjunctive treatments with antibiotics, anti-leukotrienes, and other topical therapies have been investigated and may benefit certain patient populations, but convincing evidence does not exist to warrant addition of these treatments to the standard of care for CRSwNP. Conclusions Topical steroid therapy is clearly effective for CRSwNP, and recent studies demonstrate the safety and efficacy of high-dose nasal steroid rinses. Alternate delivery methods for local steroids may be useful for patients who are not responding to or who are noncompliant with conventional intranasal corticosteroid sprays and rinses. Future studies are needed to clarify if oral or topical antibiotics, oral anti-leukotrienes, or other novel therapies are significantly effective in decreasing symptoms and improving the quality of life in patients with CRSwNP.
Trends and Outcomes of ST‐Segment–Elevation Myocardial Infarction Among Young Women in the United States
Abe, Temidayo , Olanipekun, Titilope , Adedinsewo, Demilade , Ogunmoroti, Oluseye , Udongwo, Ndausung , Effoe, Valery , Rice, Bria , Onuorah, Ifeoma , Ghali, Jalal K. , Michos, Erin D , Rice, Bria J , Adedinsewo, Demilade A , Mehta, Puja K. , Michos, Erin D.

Mayo Clinic

Journal of the American Heart Association | February 27, 2023 | Volume: 12 | Issue: 5 | Pages: No page available

10.1161/jaha.122.026811 | PMID 36847058 Get It

Background Although there has been a decrease in the incidence of ST‐segment–elevation myocardial infarction (STEMI) in the United States, this trend might be stagnant or increasing in young women. We assessed the trends, characteristics, and outcomes of STEMI in women aged 18 to 55 years. Methods and Results We identified 177 602 women aged 18 to 55 with the primary diagnosis of STEMI from the National Inpatient Sample during years 2008 to 2019. We performed trend analyses to assess hospitalization rates, cardiovascular disease (CVD) risk factor profile, and in‐hospital outcomes stratified by three age subgroups (18–34, 35–44, and 45–55 years). We found STEMI hospitalization rates were decreased in the overall study cohort from 52 per 100 000 hospitalizations in 2008 to 36 per 100 000 in 2019. This was driven by decreased proportion of hospitalizations in women aged 45 to 55 years (74.2% to–71.7%; P <0.001). Proportion of STEMI hospitalizationincreased in women aged 18–34 (4.7%–5.5%; P <0.001) and 35–44 years (21.2%–22.7%; P <0.001). The prevalence of traditional and non‐traditional female‐specific or female‐predominant CVD risk factors increased in all age subgroups. The adjusted odds of in‐hospital mortality in the overall study cohort and age subgroups were unchanged throughout the study period. Additionally, we observed an increase in the adjusted odds of cardiogenic shock, acute stroke, and acute kidney injury in the overall cohort over the study period. Conclusions STEMI hospitalizations are increasing among women aged <45 years, and in‐hospital mortality has not changed over the past 12 years in women aged <55 years. Future studies on the optimization of risk assessment and management of STEMI in young women are urgently needed.
Imaging and pathologic correlation of composite pheochromocytoma-ganglioneuroma
Janiszewski, Robert A, Pham, Mitchel, Stanton, Melissa, Nguyen, Ba D. , Stanton, Melissa L, Nguyen, B D

Mayo Clinic

Japanese Journal of Clinical Oncology | February 27, 2023 | Volume: 53 | Issue: 5 | Pages: 452-453

10.1093/jjco/hyad010 | PMID 36846927 Get It

Change in Cerebrospinal Fluid Tau Microtubule Binding Region Detects Symptom Onset, Cognitive Decline, Tangles, and Atrophy in Dominantly Inherited Alzheimer's Disease
Li, Yan , Barthélemy, Nicolas R. , Gordon, Brian A. , Hassenstab, Jason , Fagan, Anne M. , Morris, John C. , Xiong, Chengjie , Méndez, Patricio Chrem, Noble, James M. , Farlow, Martin R. , Chhatwal, Jasmeer P. , Day, Gregory S. , Masters, Colin L. , Roh, Jee Hoon , Sachdev, Pallavi, Koyama, Akihiko , Reyderman, Larisa, Bateman, Randall J. , Network, and the Dominantly Inherited Alzheimer, Sachdev, Perminder S. , Vöglein, Jonathan , Gordon, Brian A , Kasuga, Kensaku , Day, Gregory S , Jucker, Mathias , Roh, Jee Hoon , Sato, Chihiro , McDade, Eric M , Sachdev, Perminder S , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Hassenstab, Jason , Morris, John C , Noble, James M , Horie, Kanta , Li, Yan, Benzinger, Tammie L.S. , Karch, Celeste M. , Xiong, Chengjie , Allegri, Ricardo , Ikeuchi, Takeshi , Schofield, Peter R. , Lee, Jae‐Hong , Sachdev, Pallavi, McDade, Eric , Network, and the Dominantly Inherited Alzheimer

Mayo Clinic

Annals of Neurology | February 27, 2023 | Volume: 93 | Issue: 6 | Pages: 1158-1172

10.1002/ana.26620 | PMID 36843330 Get It

ObjectiveIdentifying cerebrospinal fluid measures of the microtubule binding region of tau (MTBR‐tau) species that reflect tau aggregation could provide fluid biomarkers that track Alzheimer's disease related neurofibrillary tau pathological changes. We examined the cerebrospinal fluid (CSF) MTBR‐tau species in dominantly inherited Alzheimer's disease (DIAD) mutation carriers to assess the association with Alzheimer's disease (AD) biomarkers and clinical symptoms.MethodsCross‐sectional and longitudinal CSF from 229 DIAD mutation carriers and 130 mutation non‐carriers had sequential characterization of N‐terminal/mid‐domain phosphorylated tau (p‐tau) followed by MTBR‐tau species and tau positron emission tomography (tau PET), other soluble tau and amyloid biomarkers, comprehensive clinical and cognitive assessments, and brain magnetic resonance imaging of atrophy.ResultsCSF MTBR‐tau species located within the putative “border” region and one species corresponding to the “core” region of aggregates in neurofibrillary tangles (NFTs) increased during the presymptomatic stage and decreased during the symptomatic stage. The “border” MTBR‐tau species were associated with amyloid pathology and CSF p‐tau; whereas the “core” MTBR‐tau species were associated stronger with tau PET and CSF measures of neurodegeneration. The ratio of the border to the core species provided a continuous measure of increasing amounts that tracked clinical progression and NFTs.InterpretationChanges in CSF soluble MTBR‐tau species preceded the onset of dementia, tau tangle increase, and atrophy in DIAD. The ratio of 4R‐specific MTBR‐tau (border) to the NFT (core) MTBR‐tau species corresponds to the pathology of NFTs in DIAD and change with disease progression. The dynamics between different MTBR‐tau species in the CSF may serve as a marker of tau‐related disease progression and target engagement of anti‐tau therapeutics. ANN NEUROL 2023;93:1158–1172
Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
Duin, Isabella A.J. van , Elias, Sjoerd G. , Eertwegh, Alfonsus Johannes Maria van den, Groot, Jan Willem B. de , Diest, P. J. van , Verheijden, Rik J. , Not, Olivier J. van , Aarts, Maureen J.B. , Berkmortel, Franchette W.P.J. van den , Blank, Christian U. , Kamphuis, Anna M., Piersma, Djura , Rijn, Rozemarijn S. van, Veldt, Astrid A.M. van der , Vreugdenhil, Gerard , Boer, Marion A. M. Stevense‐den, Boers‐Sonderen, Marye J. , Kapiteijn, Ellen , van Duin, Isabella A J , van Diest, Paul J , Blokx, Willeke A.M. , Leiner, Tim , Verhoeff, Joost J.C. , Haanen, John B A G , Hospers, Geke A.P. , Wouters, Michel W.J.M. , Suijkerbuijk, Karijn P.M.

Mayo Clinic

International Journal of Cancer | February 27, 2023 | Volume: 152 | Issue: 12 | Pages: 2493-2502

10.1002/ijc.34479 | PMID 36843274 Get It

AbstractSince the introduction of BRAF(/MEK) inhibition and immune checkpoint inhibition (ICI), the prognosis of advanced melanoma has greatly improved. Melanoma is known for its remarkably long time to first distant recurrence (TFDR), which can be decades in some patients and is partly attributed to immune‐surveillance. We investigated the relationship between TFDR and patient outcomes after systemic treatment for advanced melanoma. We selected patients undergoing first‐line systemic therapy for advanced melanoma from the nationwide Dutch Melanoma Treatment Registry. The association between TFDR and progression‐free survival (PFS) and overall survival (OS) was assessed by Cox proportional hazard regression models. The TFDR was modeled categorically, linearly, and flexibly using restricted cubic splines. Patients received anti‐PD‐1‐based treatment (n = 1844) or BRAF(/MEK) inhibition (n = 1618). For ICI‐treated patients with a TFDR <2 years, median OS was 25.0 months, compared to 37.3 months for a TFDR >5 years (P = .014). Patients treated with BRAF(/MEK) inhibition with a longer TFDR also had a significantly longer median OS (8.6 months for TFDR <2 years compared to 11.1 months for >5 years, P = .004). The hazard of dying rapidly decreased with increasing TFDR until approximately 5 years (HR 0.87), after which the hazard of dying further decreased with increasing TFDR, but less strongly (HR 0.82 for a TFDR of 10 years and HR 0.79 for a TFDR of 15 years). Results were similar when stratifying for type of treatment. Advanced melanoma patients with longer TFDR have a prolonged PFS and OS, irrespective of being treated with first‐line ICI or targeted therapy.
Left Atrial Enlargement is Associated with Pulmonary Vascular Disease in Heart Failure with Preserved Ejection Fraction
Gard, E. , Beale, A. , Telles, Fernando , Silvestry, Frank E. , Hanff, Thomas C. , Hummel, Scott L. , Komtebedde, Jan , Nanayakkara, Shane , Hummel, Scott L , Litwin, Sheldon E. , Petrie, Mark C. , Shah, Sanjiv J , Borlaug, Barry A. , Burkhoff, Daniel , Kaye, David M.

Mayo Clinic

European Journal of Heart Failure | February 27, 2023 | Volume: 25 | Issue: 6 | Pages: 806-814

10.1002/ejhf.2805 | PMID 36847073 Get It

ABSTRACT Aims Elevated left atrial (LA) pressure is a pathophysiologic hallmark of heart failure with preserved ejection fraction (HFpEF). Chronically elevated LA pressure leads to LA enlargement, which may impair LA function and increase pulmonary pressures. We sought to evaluate the relationship between LA volume and pulmonary arterial haemodynamics in patients with HFpEF. Methods and results Data from 85 patients (aged 69 ± 8 years) who underwent exercise right heart catheterization and echocardiography were retrospectively analysed. All had symptoms of heart failure, left ventricular ejection fraction ≥50% and haemodynamic features of HFpEF. Patients were divided into LA volume index-based tertiles (≤34 ml/m2, &gt;34 to ≤45 ml/m2, &gt;45 ml/m2). A subgroup analysis was performed in patients with recorded LA global reservoir strain (n = 60), with reduced strain defined as ≤24%. Age, sex, body surface area and left ventricular ejection fraction were similar between volume groups. LA volume was associated with blunted increases in cardiac output with exercise (padjusted &lt;0.001), higher resting mean pulmonary artery pressure (padjusted = 0.003), with similar wedge pressure (padjusted = 1). Pulmonary vascular resistance (PVR) increased with increasing LA volume (padjusted &lt;0.001). Larger LA volumes featured reduced LA strain (padjusted &lt;0.001), with reduced strain associated with reduced PVR–compliance time (0.34 [0.28–0.40] vs. 0.38 [0.33–0.43], p = 0.03). Conclusion Increasing LA volume may be associated with more advanced pulmonary vascular disease in HFpEF, featuring higher PVR and pulmonary pressures. Reduced LA function, worse at increasing LA volumes, is associated with a disrupted PVR–compliance relationship, further augmenting impaired pulmonary haemodynamics.
The role of PGM1isoform 2 in PGM1‐CDG: One step closer to genotype–phenotype correlation?
Radenkovic, Silvia , Laerdahl, Jon K. , Backe, Paul Hoff , Morava, Éva

Mayo Clinic

Journal of Inherited Metabolic Disease | February 27, 2023 | Volume: 46 | Issue: 2 | Pages: 159-160

10.1002/jimd.12601 | PMID 36843136 Get It

Click here to access the podcast for this paper.
Safety and Tolerability of Concentrated Intraventricular Nicardipine for Poor-Grade Aneurysmal Subarachnoid Hemorrhage–Related Vasospasm
Zahra, Kaneez , Santos, Christan D. , Peacock, Sarah , Jackson, Daniel A., Siegel, Jason , Freeman, William D. , Peacock, Sarah H, Siegel, Jason L, Freeman, William D , Domingo, Ricardo A. , Turnbull, Marion T. , Tawk, Rabih G.

Mayo Clinic

Journal of Personalized Medicine | February 27, 2023 | Volume: 13 | Issue: 3 | Pages: 428

10.3390/jpm13030428 | PMID 36983610 Get It

Objective: To report the preliminary safety, tolerability, and cerebral spinal fluid (CSF) sampling utility of serial injections of concentrated intraventricular nicardipine (IVN) in the treatment of aneurysmal subarachnoid hemorrhage (aSAH). Methods: We report the clinical, radiographic, and laboratory safety and tolerability data of a retrospective case series from a single academic medical center. All patients with aSAH developed vasospasm despite enteral nimodipine and received serial injections of concentrated IVN (2.5 mg/mL). CSF injection safety, tolerability, and utility are defined and reported. Results: A total of 59 doses of concentrated IVN were administered to three patients with poor-grade SAH. In Case 1, a 33-year-old man with modified Fisher scale (mFS) grade 4 and Hunt-Hess scale (HH) score 4 received 26 doses; in Case 2, a 36-year-old woman with mFS grade 4 and HH score 5 received 13 doses; and in Case 3, a 70-year-old woman with mFS grade 3 and HH score 4 received 20 doses. No major safety or tolerability events occurred. Two patients were discharged to a rehabilitation facility, and one died after discharge from the hospital. Conclusions: A concentrated 4 mg IVN dose (2.5 mg/mL) in a 1.6 mL injection appears relatively safe and tolerable and potentially offers a second-line strategy for treating refractory vasospasm in poor-grade SAH without compromising intracranial pressure or cerebral perfusion pressure.